Inventor
Lisa A. Hasvold
Inventor
Grayslake, IL, US
Overview
Patents· 32 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Dprimary
C07DHeterocyclic compounds36%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations31%
A61KPreparations for medical, dental or toiletry purposes25%
Y02ATechnologies for adaptation to climate change6%
Y02PClimate change mitigation technologies in the production or processing of goods2%
PatentTitleYear
10,633,379Bromodomain inhibitors202010,131,657Bromodomain inhibitors201810,035,800Substituted 1,4,10-triazadibenzo[cd,f]azulenes, substituted 1,4,5,10-tetraazadibenzo[cd,f]azulenes and substituted 1,4,5,7,10-pentaazadibenzo[cd,f]azulenes as bromodomain inhibitors20189,957,263Bromodomain inhibitors20189,776,990'Isoindolone derivatives'20179,493,411'Pyrrole-3-carboxamide bromodomain inhibitors'20169,359,296'7-substituted indole Mcl-1 inhibitors'20169,321,764'Dihydro-pyrrolopyridinone inhibitors'20169,315,488'Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases'20169,303,025'Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases'20169,296,741'Bromodomain inhibitors'20169,174,982'Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases'20159,125,913'Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases'20159,073,855'BCL-2 selective apoptosis-inducing agents for the treatment of cancer and immune diseases'20159,072,748'BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases'20159,050,346'Bromodomain inhibitors'20159,045,420'Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases'20159,034,875'Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases'20159,035,047'7-substituted indole Mcl-1 inhibitors'20158,980,879'Bromodomain inhibitors'20158,586,754'BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases'20138,580,794'Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases'20138,563,735'Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases'20138,546,399'Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases'20138,445,679'7-substituted indole MCL-1 inhibitors'20138,232,273'Heterocyclic compounds and methods of use'20128,148,384'Substituted thieno[3,2-d]pyrimidine PIM kinase inhibitors as cancer chemotherapeutics'20127,456,169'Heterocyclic kinase inhibitors'20087,323,570'Farnesyltransferase inhibitors'20087,211,595'Farnesyltransferase inhibitors'20075,837,868'Process for preparation of chiral 3-amino-pyrrolidine and analogous bicyclic compounds'19985,703,244'Process for preparation of chiral 3-amino-pyrrolidine and analogous bicyclic compounds'1997Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
1997–2012Patents assigned to ABBOTT LAB (7)· patent assignee history
1997–2020Based in Grayslake, IL, US· patent location history
2012–2013Patents assigned to TAO ZHI-FU (7)· patent assignee history
2012–2013Patents assigned to WANG LE (7)· patent assignee history
2012–2013Patents assigned to ELMORE STEVEN W (6)· patent assignee history
2013–2020Patents assigned to ABBVIE INC (25)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| ABBVIE INC | 25 | 2013–2020 |
| ABBOTT LAB | 7 | 1997–2012 |
| TAO ZHI-FU | 7 | 2012–2013 |
| WANG LE | 7 | 2012–2013 |
| ELMORE STEVEN W | 6 | 2012–2013 |
Locations
| Location | Patents | Span |
|---|---|---|
| Grayslake, Illinois, US | 32 | 1997–2020 |